Cargo Therapeutics(CRGX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., November 12, 2024 ...